Cx43 enhances response to BRAF/MEK inhibitors by reducing DNA repair capacity.
Loading...
Embargo End Date
ICR Authors
Authors
Varela-Vázquez, A
Guitián-Caamaño, A
Carpintero-Fernández, P
Carneiro-Figueira, A
Álvarez, V
Varela-Eirín, M
Calleja-Chuclá, T
Bravo-López, SB
Vidal, A
Sendón-Lago, J
Mateos, MR-C
Caeiro, JR
Sanz-Moreno, V
Aasen, T
Blanco, MG
Sabio, G
Quindós, M
Rivas, C
Santamaría, D
Fernandez-Lozano, C
Fonseca, E
Huertas, P
Sánchez-Laorden, B
Alabert, C
Mayán, MD
Guitián-Caamaño, A
Carpintero-Fernández, P
Carneiro-Figueira, A
Álvarez, V
Varela-Eirín, M
Calleja-Chuclá, T
Bravo-López, SB
Vidal, A
Sendón-Lago, J
Mateos, MR-C
Caeiro, JR
Sanz-Moreno, V
Aasen, T
Blanco, MG
Sabio, G
Quindós, M
Rivas, C
Santamaría, D
Fernandez-Lozano, C
Fonseca, E
Huertas, P
Sánchez-Laorden, B
Alabert, C
Mayán, MD
Document Type
Journal Article
Date
2025-07-04
Date Accepted
2025-06-09
Abstract
BRAF and MEK inhibitors (BRAF/MEKi) have radically changed the treatment landscape of advanced BRAF mutation-positive tumours. However, limited efficacy and emergence of drug resistance are major barriers for successful treatments. Here, by using relevant preclinical models, we find that Connexin43 (Cx43), a protein that plays a role in cell-to-cell communication, enhances the effectiveness of BRAF/MEKi by recruiting DNA repair complexes to lamin-associated domains and promoting persistent DNA damage and cellular senescence. The nuclear compartmentalization promoted by Cx43 contributes to genome instability and synthetic lethality caused by excessive DNA damage, which could provide a therapeutic approach for these tumours to overcome drug resistance. Based on these findings, we designed a drug combination using small extracellular vesicles (sEVs) to deliver the full-Cx43 in combination with the BRAF/MEKi. This study reveals Cx43 as a regulator of DNA repair and BRAF/MEKi response, highlighting the therapeutic potential that this approach could eventually have in the clinic to overcome the limitations of current therapies and improve treatment outcomes for patients with advanced BRAF mutant tumours.
Citation
Nature Communications, 2025, 16 (1), pp. 6168 -
Source Title
Nature Communications
Publisher
NATURE PORTFOLIO
ISSN
2041-1723
eISSN
2041-1723